ArticleCancers2021
ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Respiratory muscle training with electronic devices in the postoperative period of hepatectomy: A randomized study.World journal of hepatology · 2023Trial
- Machine learning models classifiers enable a strong prediction of radioembolization-induced liver disease, and define a new bilirubin threshold for selection of patients.European journal of nuclear medicine and molecular imaging · 2026Article
- Selective Internal Radiation Therapy (SIRT) for Hepatocellular Carcinoma: Real-World Experience from a Tertiary Care Centre.Journal of clinical medicine · 2026Article
- Role of Liver Function in the Multiparametric Assessment of Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2026Review
- LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab.Frontiers in oncology · 2026Article
- Impact of Child Pugh B Stage for the Treatment of Advanced HCC.Journal of hepatocellular carcinoma · 2026Review
- Theranostic Radioembolization: Radiation Dosimetry-Guided Treatment Planning and Delivery.World journal of nuclear medicine · 2025Review
- Albi score predicts overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with selective internal radiation therapy (SIRT).La Radiologia medica · 2025Article
- PET/CT-Based Absorbed Dose Maps inJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma.Seminars in interventional radiology · 2024Review
- Article
- Surgical resection versus transarterial chemoembolization for patients with hepatocellular carcinoma beyond Milan criteria: prognostic role of tumor burden score.Scientific reports · 2023Article
- Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study.Therapeutic advances in gastroenterology · 2023Article
- Article
- Article
- Article
- Loco-regional treatments of unresectable hepatocellular carcinoma: safety first.Hepatobiliary surgery and nutrition · 2022Article
- Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria.Current oncology (Toronto, Ont.) · 2022Review
- A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma.Cancers · 2022Article
- ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization.Frontiers in nuclear medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelective internal radiation therapy (SIRT) is an innovative treatment of hepatocellular carcinoma (HCC). The albumin-bilirubin (ALBI) score was designed to better evaluate liver functions in HCC.
methodsWe studied, retrospectively, data from patients treated with SIRT for HCC. The primary endpoint was the occurrence of radioembolization-induced liver disease (REILD). The secondary endpoint was overall survival (OS).
results222 patients were studied. The ALBI grade 1 patients had significantly less REILD (3.4%) after the first SIRT than ALBI grade 2 or 3 patients (16.8%,
conclusionsThe baseline ALBI grade is a strong predictor of REILD. The baseline ALBI score and variations of ALBI are prognostic after SIRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.